Skip to main content
. Author manuscript; available in PMC: 2023 Mar 6.
Published in final edited form as: Leukemia. 2022 May 26;36(8):1969–1979. doi: 10.1038/s41375-022-01601-5

Figure 2. Deletion of Cxcl12 from Prx1+ mesenchymal cells modulate leukemia dynamics in MLL::AF9-driven AML.

Figure 2

(A) Schematic overview of the experimental design for AML induction in the Prx1-Cxcl12 mice. (B) Bone marrow analysis showing the frequency of CD45.1leukemic cells(left panel)and the frequency of LSCs (CD45.1+,Linlow, c-Kithigh, Sca1-, CD34+, CD16/32+)(right panel).(C) Kaplan-Meier curve showing survival of C57BL6J mice (n=11/group) transplanted with equal numbers of LSCs from Prx1-Cxcl12-Mut (n=6) and Prx1-Cxcl12-Ctrl (n=6) animals. Data are representative of at least 2 independent experiments. n=5 to 6 mice per genotype per experiment unless otherwise stated. Data are represented as mean and SD. * P< .05; ** P< .01; *** P< .001.